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Background
Human follicle stimulating hormone (hFSH), synthesized
by the human pituitary gland, is a biologically active glyc-
oprotein composed of two noncovalently bound α- and
β- subunits and is critically involved in the maturation of
ovarian follicles and in spermatogenesis. Considerable
heterogeneity associated with different hFSH preparations
has been reported, mainly related to the presence of differ-
ent glycoforms [1]. The characterization of preparations of
hFSH utilized as a therapeutic agent in reproductive med-
icine is therefore very important, especially considering
that no specific monography has yet been published by
the main pharmacopoeias.
In this work four hFSH preparations were analyzed, two of
them being natural (pituitary- and urinary-derived) and
the other two recombinant (CHO-derived). Studies were
conducted to assess and compare hydrophobicity, molec-
ular weight, charge heterogeneity and purity of the natural
and recombinant heterodimeric preparations. These char-
acteristics were examined by reversed-phase high per-
formance liquid chromatography (RP-HPLC), matrix-
assisted laser desorption ionization time of flight mass
spectrometry (MALDI-TOF), isoelectric focusing and size-
exclusion high performance liquid chromatography
(HPSEC).
Results
RP-HPLC analysis indicated a significant difference (p <
0.005) between the retention time (tR) of the pituitary and
of the two recombinant FSH preparations. Urinary-
derived hFSH was found more heterogeneous than the
other three preparations. HPSEC analysis showed a signif-
icant difference (p < 0.001) between the tR of the urinary
preparation and that of the pituitary or of the recom-
binant preparations. Urinary-derived hFSH presented the
lowest HPSEC tR, in agreement with the highest molecular
mass more accurately determined by MALDI-TOF mass
spectrometry. The relative molecular mass (Mr) for the
heterodimeric form of urinary, pituitary and recombinant
hFSH preparations was 32527, 29176 and 28536 respec-
tively.
An efficient subunit dissociation process (dissociation
yield of 95%) was also set up by incubating pituitary- and
CHO-derived FSH preparations with 3 M acetic acid, over-
night, at 37°C. Yields of approximately 52% and 48% for
the β and α subunit respectively were obtained via RP-
HPLC, in agreement with theoretical yields based on the
mass determined in this work via MALDI-TOF mass spec-
trometry (53% and 47%). The Mr of the individual subu-
nits determined by this methodology for pituitary- and
CHO-derived hFSH were respectively 14467 and 14082
for the α subunit and 16509 and 16067 for the β subunit.
The urinary preparation presented a Mr of 15139 for the α
subunit and of 17196 for the β subunit (see Table 1). All
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subunits, when analyzed on RP-HPLC, presented reten-
tion times significantly different from the retention time
of the heterodimer (p < 0.01) and between them (p <
0.001). The mean relative retention times (tRR = tR subu-
nit/tR heterodimer), though, were found highly constant,
1.100 ± 0.004 (CV = 0.4%) and 1.517 ± 0.023 (CV =
1.5%), respectively for the β- and α-subunit of the three
preparations (see Table 2)
Conclusion
Different isoforms were observed, by RP-HPLC, in the
analysis of hFSH preparations of different origins (CHO,
urinary and pituitary-derived). While the recombinant
and pituitary hFSH preparations presented one main
peak, the urinary-derived hFSH presented two major iso-
forms, one of which was equivalent to the major form of
the other preparations. The other form could be an oxi-
dized form of FSH present in this urinary preparation in
high amount, as reported [2]. The RP-HPLC characteriza-
tion of the hFSH heterodimer and of individual subunits
revealed differences in hydrophobicity in the following
order: α-subunit > β-subunit > heterodimer. For the first
time a quite satisfactory separation of the heterodimer
from the dissociated β-subunit was attained.
Urinary-derived hFSH showed a higher Mr (11–14%)
when compared with pituitary and recombinant hFSH,
while pituitary hFSH showed a slightly higher Mr (~ 2%)
in comparison with the recombinant preparation.
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Table 2: Retention times of heterodimeric hFSH before dissociation, of α-and β-subunits after dissociation and relative retention times 
(tRR) of the α and β subunits with basis on heterodimeric hFSH, determined on RP-HPLC (n = 2).
SAMPLE heterodimer tR β-subunit tR α-subunit tR β-subunit tRRa α-subunit tRRa
p-hFSH 24.43 ± 0.156 26.98 ± 0.160 36.63 ± 0.198 1.104 1.499
r-hFSH Gonal F 25.19 ± 0.129 27.62 ± 0.235 38.86 ± 0.214 1.096 1.543
r-hFSH Puregon 25.29 ± 0.070 27.85 ± 0.131 38.16 ± 0.127 1.101 1.509
atRR, (relative retention time) = tRsubunit/tRheterodimer
Table 1: Relative molecular mass (Mr) of the heterodimer (α+β) and related subunits of different hFSH preparations, determined by 
Maldi-Tof mass spectrometry
Heterodimer
Preparation α-subunit β-subunit Experimental Calculated α+β Calc/Exp
p-hFSH 14467 16509 29176 30976 1.06
r-hFSH 14082 16067 28536 30149 1.06
u-hFSH 15139 17196 32527 32335 0.99Page 2 of 2
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